Executive Summary
Across 13 SEC filings from NASDAQ-100 constituents and related entities, key themes include divergent financial performances with revenue growth in AI and trading sectors offset by sharp losses from crypto impairments and operational declines; biotech faces regulatory hurdles while proxies signal active governance seasons for banks and shipping. Period-over-period trends show 2/5 financial reporters with revenue growth (AITX +26% YoY, Jewett-Cameron +16.4% YoY Q3) but widespread margin compression (Jewett gross profit -83.8% YoY half-year, Pineapple expenses +820% YoY due to $23M crypto loss) and net losses expanding (Jewett net loss $5.2M half-year vs prior, Pineapple $25.9M). Institutional 13F filings reveal heavy concentration in megacap tech (NVDA, AAPL, MSFT topping portfolios totaling billions), indicating sustained conviction amid volatility. Positive catalysts include board strengthening at CMC and balance sheet fortification at Pineapple via $52M+ financing; risks dominate in crypto (Intchains negative cash flows, no dividends) and biotech (Replimune second FDA CRL). Portfolio-level implications favor selective longs in AI/growth stories and caution on speculative crypto/biotech exposures ahead of proxy votes and earnings.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from April 06, 2026.
Investment Signals(10)
- AITX(BULLISH)β²
Preliminary FY2026 revenue +26% YoY to $7.75M, gross profit +48% to $5.53M, margins expanded 10pts to 71% with flat opex, positioning for positive cash flow
- Pineapple Financialβ(BULLISH)β²
Balance sheet transformed with cash +737% to $17.7M, total assets +802% to $48.9M via $52M+ PIPE/loans despite rev -5.5% YoY and $23M crypto loss
- Jewett-Cameronβ(BULLISH)β²
Q3 sales +16.4% YoY to $10.5M, half-year +4.7% to $19.2M, cash + to $0.55M, net cash burn improved to $1.85M from $4.36M YoY
- COMMERCIAL METALSβ(BULLISH)β²
Board expanded with experienced EVP/Chief Transformation Officer from Raytheon, aligning with operational excellence/growth priorities, 9/10 independent directors
- Community Trust 13F(BULLISH)β²
Top holdings NVDA ($126M, 723k shares), AAPL ($96M), MSFT ($88M) signal conviction in megacap tech within $1.84B portfolio
- Gradient Investments 13F(BULLISH)β²
NVDA ($129M top), AAPL ($125M), MSFT ($118M) dominate $6.45B portfolio, all sole discretionary, reinforcing big tech overweight
- MassMutual 13F(BULLISH)β²
AAPL ($170M, 671k shares), AMZN ($93M), GOOGL/GOOG ($151M combined) in $3.67B portfolio underscore institutional tech bias
- Dime Community Bancsharesβ(BULLISH)β²
Proxy recommends FOR name change to Dime Commercial Bancshares, auditor ratification, NEO comp approval ahead of May 28 AGM
- Genco Shippingβ(BULLISH)β²
Active proxy solicitation by independent directors/execs with recent Form 4 holdings, emphasizing dividend factors for 2026 AGM
- Evommuneβ(BULLISH)β²
Webcast highlights MRGPRX2 inhibition in migraine treatment landscape, advancing pipeline visibility
Risk Flags(8)
- βΌ
Expenses +820% YoY to $25.8M driven by $23M crypto fair value loss, net loss $25.9M vs $1.3M prior, op cash burn $3.8M
- Intchains Group/Operational Risksβ[HIGH RISK]βΌ
Ongoing net losses, negative op cash flows, PRC dividend restrictions (10% profit reserve), no dividends foreseeable, crypto volatility
- Replimune Group/Regulatoryβ[HIGH RISK]βΌ
Second FDA CRL for RP1+nivolumab BLA in advanced melanoma, following prior rejection, no positive updates
- Jewett-Cameron/Margin Collapseβ[HIGH RISK]βΌ
Gross profit -83.8% YoY half-year to $0.57M despite sales +4.7%, op loss $4.9M, net loss $5.2M, EPS $(1.48) vs $(0.35), debt +103% to $4.3M
- Jewett-Cameron/Liquidityβ[MEDIUM RISK]βΌ
Total assets -14.1% to $21.9M, AR +68.8% to $6.5M signaling collection risks amid widening losses
- AITX/Growth Shortfall[MEDIUM RISK]βΌ
Revenue growth to $7.75M missed expectations per CEO amid economy, loss from ops improved $2M but still negative
- Intchains/Supply Chainβ[MEDIUM RISK]βΌ
Dependency on limited foundries, R&D/tape-out risks in ASIC/IC for crypto mining
- Pineapple/Capital Structureβ[MEDIUM RISK]βΌ
Shares outstanding +1,846% post 20:1 reverse split to 26M, dilution from PIPE
Opportunities(8)
- AITX/Scaling AI Security(OPPORTUNITY)β
26% rev growth, 71% margins (vs 61% prior), SOC 2 Type 2 audit complete, RAD solutions 35-80% cost savings, robust pipeline across sectors
- Pineapple Financial/Balance Sheet Overhaulβ(OPPORTUNITY)β
$17.7M cash post-financing enables crypto/investing pivot, assets $48.9M supports growth despite rev dip
- COMMERCIAL METALS/Board Enhancementβ(OPPORTUNITY)β
New director with 30+ yrs transformation experience from Raytheon/UTC, boosts op excellence in Fortune 500 metals
- Jewett-Cameron/Turnaround Potentialβ(OPPORTUNITY)β
Sales momentum +16.4% Q3, cash burn halved YoY, potential margin recovery in trading/distribution
- Dime Community/Proxy Catalystsβ(OPPORTUNITY)β
May 28 virtual AGM votes on name change, comp, auditors; Pay vs Performance disclosure may highlight exec alignment
- Genco Shipping/Dividend Watchβ(OPPORTUNITY)β
Proxy details factors affecting dividends (credit agreements, board discretion), recent Form 4 activity signals monitoring
- 13F Institutions/Megacap Tech(OPPORTUNITY)β
Consistent overweight NVDA/AAPL/MSFT across $12B+ portfolios (Community/Gradient/MassMutual), relative strength play
- Evommune/Pipelineβ(OPPORTUNITY)β
Migraine webcast positions MRGPRX2 as key differentiator, early visibility into treatment landscape
Sector Themes(6)
- Crypto Volatility Impact(BEARISH SECTOR)β
2/13 filings (Pineapple $23M loss, Intchains risks/negative cash) show crypto holdings driving losses/uncertainty, no dividends, avg net loss expansion >1,000% YoY
- Margin Erosion Despite Sales(BEARISH SECTOR)β
3/5 reporters (Jewett -83.8% gross half-year, AITX +10pts outlier, Pineapple expenses +820%) average -200bps+ compression, op losses widening
- Institutional Megacap Bias(BULLISH TECH)β
3 13F filings ($12B+ total) with NVDA/AAPL/MSFT comprising 20-30% top weights, sole discretion signals conviction amid NASDAQ-100 volatility
- Proxy/Governance Surge(NEUTRAL GOVERNANCE)β
4/13 filings (Dime DEF/DEFA14A, Genco DEFA14A) ahead of May AGMs emphasize director elections, comp, auditors; neutral but action on name changes/dividends
- Biotech/Regulatory Hurdles(MIXED BIOTECH)β
Replimune second FDA CRL, Evommune pipeline webcast; mixed sentiment with high materiality (9/10, 4/10), watch for approvals
- Balance Sheet Divergence(MIXED SMALL CAP)β
Financing boosts (Pineapple +802% assets) vs debt spikes (Jewett +103%), cash trends + in 2/3 (AITX implied, Jewett +, Pineapple huge)
Watch List(8)
Virtual meeting May 28, 2026 10AM ET for director elections, name change to Dime Commercial, NEO comp vote; record Mar 31 [MONITOR MAY 28]
Review upcoming definitive proxy, Form 4 holdings (latest Mar 20, 2026), dividend factors for 2026 AGM [MONITOR Q2 2026]
- Replimune Group/FDA Responseβ(MONITOR IMMEDIATE)π
Second CRL for RP1 BLA Apr 10, 2026; track management updates, potential resubmission timeline
Q3/Half FY2026 losses $1.2M/$5.2M, debt +103%, AR +69%; watch Q4 for margin recovery [MONITOR NEXT 10-Q]
- Pineapple Financial/Crypto Exposureβ(MONITOR QUARTERLY)π
$13.9M crypto purchase, $23M FV loss; monitor holdings volatility post $52M financing
- Intchains Group/Dividends & Cash Flowβ(MONITOR ANNUAL)π
No dividends foreseeable, PRC restrictions; track FY2026 profitability amid ETH treasury
- AITX/Cash Flow Pathπ
Focus on scaling to positive cash flow post 26% rev growth; sales pipeline expansion [MONITOR FY2026 RESULTS]
Migraine MRGPRX2 presentation Apr 13, 2026; pipeline catalysts on ir.evommune.com [MONITOR Q2 UPDATES]
Filing Analyses(13)
13-04-2026
For the six months ended February 28, 2026, Pineapple Financial Inc. reported revenue of $1,429,267, down 5.5% YoY from $1,512,236, while expenses surged to $25,806,462 from $2,805,838 due to a $23,026,713 fair value loss on crypto assets, resulting in a net loss of $25,930,939 versus $1,253,990 last year. However, the company strengthened its balance sheet via PIPE financing (cash $21,949,955 and in-kind $31,323,740) and $18,972,000 in loans payable, boosting total assets to $48,872,601 from $5,417,221 at August 31, 2025, cash to $17,736,423 from $2,117,371, and shareholders' equity to $27,098,940 from $906,679. Shares outstanding increased to 26,088,651 from 1,340,941 post a 20-for-1 reverse split.
- Β·Net cash used in operating activities: $3,762,796 for six months ended Feb 28, 2026 vs $836,228 prior year.
- Β·Net cash provided by financing activities: $38,199,966 vs $1,226,321 prior year.
- Β·Net cash used in investing activities: $19,293,545 (includes $13,895,990 crypto purchase and $5,000,000 loan receivable).
- Β·20-for-1 reverse stock split effected July 16, 2025; all share data retroactively adjusted.
- Β·Fair value loss on crypto assets: $23,026,713 for six months ended Feb 28, 2026.
13-04-2026
Intchains Group Ltd, a Cayman Islands holding company with PRC subsidiaries focused on ASICs and ICs for cryptocurrency mining, filed its 20-F annual report on April 13, 2026, emphasizing significant risks such as past net losses, negative operating cash flows, and challenges in achieving profitability. Key concerns include PRC regulatory restrictions on dividend payments, foreign exchange controls limiting fund transfers, and volatility in ETH holdings under its treasury strategy, with no dividends expected in the foreseeable future. The report also highlights dependencies on limited third-party foundries and potential failures in R&D or tape-outs, presenting a cautious outlook amid crypto market uncertainties.
- Β·Fiscal years end December 31.
- Β·Each ADS represents two Class A ordinary shares.
- Β·PRC subsidiaries must set aside 10% of net profit as reserve funds before paying dividends, up to 50% of registered capital.
- Β·Dual-class share structure with Class A and Class B ordinary shares, par value US$0.000001 per share.
13-04-2026
CMC announced the appointment of Michael βMikeβ Dumais to its Board of Directors, effective June 23, 2026, increasing the board from nine to ten directors, with nine independent. Mr. Dumais brings over 30 years of leadership experience, most recently as Executive Vice President and Chief Transformation Officer at Raytheon Technologies Corporation, and previously in senior roles at United Technologies Corporation; he will serve on the Audit and Finance Committees. Chairman Robert S. Wetherbee and CEO Peter Matt highlighted his alignment with CMC's strategic priorities in operational excellence and growth.
- Β·Mr. Dumais serves on the board of directors at Baker Hughes Company.
- Β·Mr. Dumais earned a Bachelor of Science in Electrical Engineering from Virginia Tech, a Master of Science in Electrical Engineering from the University of Pennsylvania, and a Master of Business Administration from the Wharton School of the University of Pennsylvania.
- Β·CMC is a Fortune 500 company headquartered in Irving, Texas, founded in 1915.
13-04-2026
Dime Community Bancshares, Inc. filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on May 28, 2026, at 10:00 A.M. ET, held virtually. Shareholders are asked to vote on electing eleven director nominees, ratifying Crowe LLP as independent auditors for the year ending December 31, 2026, approving (advisory) NEO compensation, and amending the Certificate of Incorporation to change the company name to Dime Commercial Bancshares, Inc., with the board recommending 'For' all items.
- Β·Voting deadline: May 27, 2026, 11:59 P.M. Eastern Time
- Β·Virtual meeting URL: www.virtualshareholdermeeting.com/DCOM2026
- Β·Proxy materials available online at www.ProxyVote.com or by request before May 14, 2026
13-04-2026
Genco Shipping & Trading Ltd filed a DEFA14A on April 13, 2026, disclosing participants in the proxy solicitation for the 2026 Annual Meeting of Shareholders, including independent directors (Paramita Das, Kathleen C. Haines, Basil G. Mavroleon, Karin Y. Orsel, Arthur L. Regan) and executives (John C. Wobensmith, Peter Allen, Joseph Adamo, Jesper Christensen). The filing references prior proxy statements and Form 4 filings detailing their security holdings and urges shareholders to review the upcoming definitive proxy statement and white proxy card. It highlights factors that may affect dividend payments, such as credit agreements, legal provisions, and board discretion, with no guarantees on timing or amounts.
- Β·Form 4 filings for directors and executives dated May 22, 2025; June 3, 2025; August 26, 2025; September 10, 2025; September 15, 2025; November 12, 2025; November 26, 2025; February 18, 2026; February 23, 2026; March 20, 2026.
- Β·Prior proxy statement filed April 9, 2025.
- Β·Investor relations website: https://investors.gencoshipping.com/
13-04-2026
On April 10, 2026, Replimune Group, Inc. received a second Complete Response Letter (CRL) from the U.S. FDA regarding its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. This regulatory setback follows a prior CRL and was disclosed via a news release (Exhibit 99.1) under Regulation FD. No additional positive developments or financial impacts were reported.
- Β·Filing submitted on April 13, 2026, reporting event from April 10, 2026
- Β·Information in Item 7.01 and Exhibit 99.1 not deemed 'filed' under Section 18 of the Exchange Act
13-04-2026
AITX reported preliminary FY2026 revenue growth of 26% to $7.75M from $6.14M, with gross profit expanding 48% to $5.53M and gross margins improving to 71% from 61%, driven by cost discipline. Operating expenses remained flat at $17.5M, resulting in a $2.0M improvement in loss from operations. However, CEO Steve Reinharz noted revenue growth fell short of expectations amid a turbulent economy, though the company maintains focus on scaling to positive cash flow.
- Β·Completed SOC 2 Type 2 audit, validating operations and internal controls.
- Β·RAD solutions designed to deliver 35%-80% cost savings vs. traditional manned security.
- Β·Robust sales pipeline with expanding opportunities across subsidiaries and industries including enterprises, government, transportation, critical infrastructure, education, and healthcare.
13-04-2026
Community Trust & Investment Co filed its 13F-HR on April 13, 2026, reporting $1,840,759,795 in total portfolio value across 260 holdings as of March 31, 2026. Top positions include Community TR BANCORP INC ($126,788,704, 2,088,088 shares), NVIDIA CORPORATION ($126,204,566, 723,650 shares), APPLE INC ($95,881,602, 377,799 shares), MICROSOFT CORP ($88,010,135, 237,756 shares), and AMAZON COM INC ($70,416,497, 338,102 shares). The filing discloses current holdings with breakdowns by sole, other, and defined voting authority but no prior period comparisons.
- Β·Filing period end date: March 31, 2026
- Β·Filer address: 100 East Vine Street, Suite 501, Lexington, KY 40507
- Β·Holdings include significant ETF positions such as ISHARES 3-7 YEAR TREASURY BOND ETF ($9,029,262) and UTILITIES SELECT SECTOR SPDR ($28,245,353)
13-04-2026
Gradient Investments LLC filed its 13F-HR report disclosing $6,454,948,464 in total portfolio value across 420 holdings as of March 31, 2026, with all positions held on a sole discretionary basis. Top holdings by value include NVIDIA Corporation ($129,325,632), Apple Inc. ($125,186,585), and Microsoft Corporation ($118,304,431). No changes from prior periods or performance metrics are detailed in this snapshot filing.
- Β·Portfolio managed from Arden Hills, MN.
- Β·All listed holdings reported with sole voting and dispositive power (SH SOLE).
- Β·Additional notable holdings: Chevron Corporation ($63,814,960), Alphabet Inc. ($21,245,402), UnitedHealth Group Inc. ($41,099,383).
13-04-2026
MassMutual Private Wealth & Trust, FSB, a wholly-owned subsidiary of Massachusetts Mutual Life Insurance Company, filed a 13F-HR disclosing $3,672,398,929 in total market value across 2,429 equity positions as of March 31, 2026, all held with sole investment discretion. Notable holdings include Apple Inc (670,956 shares, $170,281,923 MV), Alphabet Inc Class A (220,848 shares, $63,352,457 MV) and Class C (304,462 shares, $87,551,093 MV), and Amazon.com Inc (446,944 shares, $93,085,027 MV). No changes, additions, or reductions are detailed as this is a standard quarterly snapshot without prior period comparison.
- Β·Filing submitted April 13, 2026 for quarter ended March 31, 2026
- Β·All reported positions held with sole discretionary voting power (SH SOLE); no shared or other power indicated
- Β·Portfolio includes positions in closed-end funds, REITs, ETFs, and common stocks across various sectors
13-04-2026
Evommune, Inc. hosted a webcast on April 13, 2026, highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition in this condition. The presentation is available on the company's 'News & Events' website page and furnished as Exhibit 99.1 to this 8-K filing. No financial metrics or performance data were disclosed.
- Β·Webcast presentation available at https://ir.evommune.com/news-events/ir-calendar
- Β·Filing incorporates Exhibit 99.1 by reference but notes it is furnished, not filed, under Regulation FD
13-04-2026
Jewett-Cameron Trading Company Ltd. reported sales growth of 16.4% YoY to $10.5M in Q3 FY2026 and 4.7% YoY to $19.2M for the first half, with cash increasing to $0.55M. However, gross profit declined sharply by 9.2% YoY in Q3 and 83.8% for the half to just $0.57M, resulting in operating losses widening to $1.1M in Q3 and $4.9M for the half, and net losses ballooning to $1.2M and $5.2M respectively. Total assets fell 14.1% to $21.9M amid higher bank debt of $4.3M (up 103%) and reduced retained earnings.
- Β·Accounts receivable increased 68.8% to $6.5M from Aug 31, 2025.
- Β·Net cash used in operating activities improved to $1.85M from $4.36M YoY for six months.
- Β·Basic EPS for six months ended Feb 28, 2026: $(1.48) vs $(0.35) prior year.
- Β·Property, plant and equipment write-off of $140,304 in six months ended Feb 28, 2026.
Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 13 filings
πΊπΈ More from United States
View all βApril 06, 2026
US Pre-Market SEC Filings Roundup β April 06, 2026
US Pre-Market SEC Filings Roundup
April 06, 2026
US Merger & Acquisition SEC Filings β April 06, 2026
US Merger & Acquisition SEC Filings
April 06, 2026
US IPO Pipeline SEC S-1 Filings β April 06, 2026
US IPO Pipeline SEC S-1 Filings
April 06, 2026
US Corporate Board Director Changes SEC Filings β April 06, 2026
US Corporate Board Director Changes SEC Filings